Innovent receives positive CHMP opinion for Zybrivo (sintilimab) as first‑line NSCLC therapy in Europe
Innovent Biologics announced that the EMA’s Committee for Medicinal Products for Human Use gave a positive opinion recommending Zybrivo (sintilimab) with chemotherapy for first‑line treatment of adult patients with advanced non‑squamous non‑small cell lung cancer. The recommendation is based on the Phase 3 ORIENT‑11 trial, which enrolled 397 patients and showed longer progression‑free and overall survival versus placebo plus chemotherapy. The European Commission will consider a final marketing‑authorization decision in the next few months.
Why it matters
If the Commission grants approval, Zybrivo could become a new revenue source for Innovent in the EU, expanding its market beyond China. The timing of the decision will affect the rollout of distribution and reimbursement arrangements across the 27 EU members, Iceland, Norway and Liechtenstein.
Key facts
- 1The CHMP issued a positive opinion recommending Zybrivo with chemotherapy for first‑line treatment of advanced non‑squamous NSCLC. prnewswire.com
- 2The opinion is based on the ORIENT‑11 Phase 3 study that enrolled 397 adult patients. finance.biggo.com
- 3In the trial, median progression‑free survival was 8.9 months for sintilimab plus chemotherapy versus 5.0 months for placebo plus chemotherapy. finance.biggo.com
- 4Median overall survival was 24.2 months with sintilimab plus chemotherapy compared with 16.8 months for the control arm. finance.biggo.com
- 5The study showed a 52% reduction in the hazard of disease progression or death for the sintilimab arm. finance.biggo.com
- 6The European Commission is expected to issue a final marketing‑authorization decision within the coming months. prnewswire.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.